In China, the incidence of primary liver cancer ranked fifth among that of malignant tumors in 2020, with 410,000 new cases, including 303,000 cases in men; the mortality rate of the cancer ranked second with 391,000 deaths in 2020, a mortality rate of 17.2/100,000 of the total population. From 2016 to 2020, global average annual incidence of primary liver cancer was 995,000 cases, with Asia 732,000 cases, accounting for 73.6%, and China 423,000 cases, accounting for 42.5%. The high incidence of liver cancer in China is highly correlated with the fact that China is a country with high prevalence of hepatitis B, environmental pollution, and some spirits-addicted residents.

Liver cancer is a common malignant tumor in China. Liver cancer starts insidiously but progresses rapidly, and by the time it is detected, it is often at an advanced stage, making the treatment of surgery ineffective. Moreover, radiotherapy is of little use in treating liver cancer. Therefore, targeted drug therapy becomes the standard treatment for patients with advanced liver cancer. Sorafenib is the world’s first multi-targeted, multi-kinase inhibitor for the treatment of liver cancer. It can directly suppress tumor growth by inhibiting RAF/MEK/ERK signaling pathway, and indirectly suppress tumor growth by blocking the formation of tumor neovascularization through inhibiting VEGFR and PDGFR. Therefore, it is the first-line drug used for the treatment of advanced primary liver cancer.

Sorafenib is a multi-kinase inhibitor originally developed by Bayer AG with the trade name of Nexavar^®. Sorafenib was approved for marketing by the FDA of U.S. in December 2005 and approved by China in August 2006. In 2017, Bayer’s sorafenib was included in the category B of China’s national medical insurance catalog after a negotiated price reduction of about 70%, and the price after inclusion in medical insurance is about CNY200 (approximately USD30.8) per tablet. From 2018 to 2021, Bayer AG continues to reduce the price of sorafenib in the Chinese market.

According to CRI’s market research, the sales value of China’s sorafenib market continued to grow from 2016 to 2019. In 2020, the sales value declined to approximately USD406 million due to COVID-19, but the CAGR from 2016 to 2020 was still up to 22.3%.

As of August 2021, besides Bayer’s sorafenib product, only generic versions of Jiangxi Shanxiang Pharmaceutical and Chongqing Yaoyou Pharmaceutical have been officially marketed in the Chinese market. Some other companies such as Yabao Pharmaceutical Group and CSPC Ouyi Pharmaceutical have filed applications for the marketing of generic sorafenib drugs. In September 2020, The China National Intellectual Property Administration issued an invalidation request review decision (No. 46292), declaring that Bayer’s patent CN200680007187.1 for sorafenib mesylate in China was invalid. The invalidation petitioner was Chongqing Yaoyou Pharmaceutical. With the invalidation of Bayer’s patent applications related to sorafenib, more generic sorafenib drugs from local Chinese pharmaceutical companies will be launched in China.

For Bayer, as more generic drugs are approved and marketed, the market share of Nexavar in China will gradually decline. Bayer is expected to stop the decline of Nexavar’s market share through measures such as price cuts.

CRI expects that from 2021 to 2025, the average sales price of sorafenib in China will decline due to fierce competition while both sales volume and value will continue to rise.

Topics Covered:

• Impact of COVID-19 on China’s Sorafenib Market
• Development Environment of Sorafenib in China
• Sales Volume of Sorafenib in China
• Sales Volume and Value of Sorafenib in China by Region
• Major Sorafenib Manufacturers in China and Their Market Shares
• Sales Price of Sorafenib in China
• Prospects of China’s Sorafenib Market, 2021-2025

Related reports:

Investigation Report on Chinese Sorafenib Market, 2018-2022

The post Research Report on China’s Sorafenib Market, 2021-2025 first appeared on CRI Report.

The global TMJ Disorder Market is expected to register a healthy market growth owing to the increase in technological advancement and increasing prevalence of these disorders. The emergence of non-surgical and surgical treatment methods for TMJ disorders is expected to drive market growth during the review period. TMJ disorders are the second-most commonly occurring musculoskeletal conditions resulting in pain and disability. The occurrences of TMD peaks from the age of 20-40 years, and it is found to be more prevalent in women than men. Additionally, women who use supplemental estrogenic or oral contraceptives are more expected to seek treatment for these conditions. Therefore, the increasing prevalence of these disorders in these populations is further fuelling the market growth during the review period.
Market Segmentation
The Global TMJ Disorders Market has been classified into Type, treatment, and end-user.
Based on type segment, the Global TMJ Disorders Market, based on Type classified into myofascial Pain, Internal Derangement (ID), and Osteoarthritis.
In terms of treatment, the market has been divided into medication, therapies, surgical, and others. The medication segment is further sub-divided into pain relievers, anti-inflammatories, tricyclic antidepressants, muscle relaxants, and others.
Based on end-user, the global TMJ disorders market is segmented into hospitals and clinics, ambulatory surgery centers, academic institutes, and others.
Regional Analysis
Geographically, the Global TMJ Disorder Market has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas market has been divided into North America and Latin America, with the North America market further segmented into the US and Canada. The Americas is expected to dominate the global market owing to the largest share of 49.20% of the TMJ disorder market in 2019. This largest share is driven by the introduction and rapid adoption of advanced treatments in the region.
The European TMJ disorder market has been bifurcated into Western Europe and Eastern Europe. The Western Europe TMJ disorder market has further been divided into Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. The TMJ disorder market in Asia-Pacific has been classified into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. The Middle East & Africa TMJ disorder market has been segmented into the Middle East and Africa.
Major Players
The key players in the global TMJ Disorders market are Abbott Laboratories, Sun Pharmaceutical Industries Limited, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Allergan, Bayer AG, Zydus Cadila, Mylan NV, Novartis International AG, and Jubilant Life Sciences Limited.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

The post Global TMJ Disorders Market Research Report—Forecast till 2027 first appeared on CRI Report.

Market Synopsis
Global Veterinary Medicine Market is anticipated to witness a healthy CAGR of 5.57% during the review period of 2020 to 2027. The rising rates of pet ownership, increasing chronic diseases, and growing consumption of meat are expected to create many growth opportunities for the global market. Apart from meat utilization, the dairy items request has likewise flooded. Expanding meat and dairy utilization request the security of domesticated animals and consistent checking of their wellbeing to capture the spread of illnesses from creatures to people. Amid the developing meat utilization, the emphasis on improving the wellbeing of new meat has expanded.
The global veterinary medicine market is expected to register a significant market owing to the largest value at USD 28,012.73 Million in 2019. The increasing predominance of diseases in animals poses a serious threat to food security. Climate change and globalization are the major reasons attributing to the rise in diseases among animals. Moreover, the increase in the number of pet ownerships is propelling the requirement for better care of companion animals, driving the overall expenditure on pets.
Market Segmentation
Global Veterinary Medicine Market has been classified into Animal Type, Product, Route of Administration, and Distribution Channel.
In terms of animal type, the global market has been divided into domesticated and companion.
In terms of product segments, the market is segmented into drugs and vaccines. By the route of administration, the market is categorized into oral, parental, and others. Based on the distribution channel, the market is divided into veterinary hospitals & clinics, retail stores, and online pharmacies.
Regional Analysis
Geographically, the Global Veterinary Medicine Market has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas is likely to contribute the largest market owing to the increase in companion animal ownership and the rising prevalence of animal diseases in the region. As per Atlas Dental, a total of 69,075 dental operations were performed in German hospitals in 2017. Additionally, the global market growth is attributed to the increasing population of pets and livestock with a high number of veterinary practices.
Europe contributes to the second-largest market in the global veterinary medicine market during the review period. The regional market is driven by the increasing prevalence of diseases, new product approvals, and the existence of developed veterinary healthcare infrastructure.
Asia-Pacific is expected to attain the fastest-growing market during the review period. The regional market is driven by the increasing penetration of the veterinary sector, the increase in the number of private veterinary clinics, growing awareness about animal welfare, and government campaigns for the welfare of pet animals in China, Japan, India, South Korea, and Australia.
The veterinary medicine market in Middle East & Africa is anticipated to register steady growth during the forecast period owing to the presence of developing countries in the region.
Major Players
The Key Players in the Global Veterinary Medicine Market are Boehringer Ingelheim, Ceva, Chanelle Pharma Group, Dechra Pharmaceuticals plc, Elanco, Merck Animal Health, Norbrook Laboratories, Vetoquinol S.A., Bayer AG, and Zoetis.

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

The post Global Veterinary Medicine Market Research Report—Forecast till 2027 first appeared on CRI Report.

The post Dietary Supplements in the Age of Personalized Nutrition Market Research Report – Global Forecast Till 2023 first appeared on CRI Report.

The post Global Active Pharmaceutical Ingredients Market Research Report – Forecast to 2023 first appeared on CRI Report.